Breaking News !! Just in time for the 2022 holiday season, when dogs often accidentally get into rich foods and trigger an acute pancreatitis attack, the FDA gave conditional approval to Panoquell-CA1 for 1 year, with the option for 4 additional annual renewals. The drug meant for injection during hospitalization for cases of pancreatitis in dogs has been approved in Japan since 2018. It's made by Ishihara Sangyo Kaisha Ltd. Below, you'll find some FAQs about this new medication and canine pancreatitis in general.
What Does Pancreatitis in Dogs Look Like?
Pancreatitis in dogs makes them feel just awful. Look for ongoing vomiting, even plain water. Look for pain in the abdomen or back. It is definitely an emergency because it's a serious and even life-threatening disease.
I've been through it just once with our (late) boy Ginko. It's very scary. Thankfully, he recovered, and it never happened again.
It can, however, become a chronic thing for some dogs, as one of our pals learned years ago.
How is Pancreatitis in Dogs Treated?
Up until now, pancreatitis in dogs “could only be managed through supportive care, such as intravenous fluids, pain medication, anti-emetics, and dietary rest,” says Steven M. Solomon, DVM, MPH, director of the FDA’s Center for Veterinary Medicine.
This conditional approval of Panoquell-CA1 gives veterinarians access to the drug sooner, which could mean faster relief for dogs who get into rich / fatty foods, which is a common trigger for actue onset pancreatitis in dogs.
What's the Active Ingredient in Panoquell-CA1?
The active ingredient called Fuzapladib sodium.
The announcement says that " when used according to the label, the drug is safe and has a reasonable expectation of effectiveness." However, the FDA plans to track any concerns and encourages dogs' families to work with their veterinarian to report any adverse events or side effects potentially related to the use of any drug, including Panoquell-CA1.
Does Panoquell-CA1 have Known Side-Effects?
Yes, potential side-effects of Panoquell-CA1 include:
- Loss of appetite
- Digestive track disorders
- Respiratory track disorders
- Liver disease and jaundice
Where Can I Learn More About Panoquell-CA1?
The FDA's announcement about conditional approval of Panoquell-CA1 provides these links to additional information: